Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Trinity Biotech (TRIB) Shares Outstanding (2017 - 2025)

Trinity Biotech's Shares Outstanding history spans 9 years, with the latest figure at $374.2 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 4.18% to $374.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $374.2 million, a 4.18% increase, with the full-year FY2025 number at $374.2 million, up 4.18% from a year prior.
  • Shares Outstanding hit $374.2 million in Q4 2025 for Trinity Biotech, up from $359.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding for TRIB hit a ceiling of $374.2 million in Q4 2025 and a floor of $83.6 million in Q4 2021.
  • Historically, Shares Outstanding has averaged $224.5 million across 5 years, with a median of $153.3 million in 2023.
  • Biggest five-year swings in Shares Outstanding: changed 0.0% in 2021 and later surged 134.29% in 2024.
  • Tracing TRIB's Shares Outstanding over 5 years: stood at $83.6 million in 2021, then surged by 82.32% to $152.4 million in 2022, then grew by 0.58% to $153.3 million in 2023, then soared by 134.29% to $359.2 million in 2024, then grew by 4.18% to $374.2 million in 2025.
  • Business Quant data shows Shares Outstanding for TRIB at $374.2 million in Q4 2025, $359.2 million in Q4 2024, and $153.3 million in Q4 2023.